Arbutus vs. Moderna Patent Case Heads to Jury Trial
Arbutus Biopharma stock rises 5% as judge orders jury trial in patent dispute over mRNA vaccine technology with Moderna, with trial set for March.
/ 904 items
#Healthcare↓
Eton Pharmaceuticals Secures Rights to First Generic Treatment for Ultra-Rare Disease
Eton Pharmaceuticals licenses U.S. rights to an ultra-rare disease treatment affecting under 100 patients, expecting FDA approval and mid-2026 launch as first generic alternative.
Wells Fargo Gives Rapport Therapeutics an “Overweight” Rating
Wells Fargo analyst rates Rapport Therapeutics as Overweight with $43 target, citing strong Phase 2a seizure data and promising efficacy.
Morgan Stanley Cuts Humana Rating Amid Medicare Advantage Concerns
Morgan Stanley downgraded Humana to Underweight, citing policy risks and disappointing Medicare Advantage updates, with a new price target of $174.
MoonLake's Sonelokimab Gets FDA Fast Track for Rare Skin Disease
MoonLake Immunotherapeutics receives FDA Fast Track designation for sonelokimab in palmoplantar pustulosis, accelerating development for this untreated skin condition.
Aquestive Therapeutics Gets FDA Feedback on Anaphylm – Quick Resolution Expected
Aquestive Therapeutics receives FDA Complete Response Letter for Anaphylm with packaging-related deficiencies. Company plans rapid resolution and Q3 2026 resubmission.